
According to Benzinga Pro data, during Q4, NovaBay Pharmaceuticals (AMEX:NBY) posted sales of $2.64 million. Earnings were up 93.1%, but NovaBay Pharmaceuticals still reported an overall loss of $158.00 thousand. NovaBay Pharmaceuticals collected $1.84 million in revenue during Q3, but reported earnings showed a $2.29 million loss.